AUPR688101A0 - Protein domains and their ligands - Google Patents
Protein domains and their ligandsInfo
- Publication number
- AUPR688101A0 AUPR688101A0 AUPR6881A AUPR688101A AUPR688101A0 AU PR688101 A0 AUPR688101 A0 AU PR688101A0 AU PR6881 A AUPR6881 A AU PR6881A AU PR688101 A AUPR688101 A AU PR688101A AU PR688101 A0 AUPR688101 A0 AU PR688101A0
- Authority
- AU
- Australia
- Prior art keywords
- ligands
- protein domains
- domains
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPR6881A AUPR688101A0 (en) | 2001-08-08 | 2001-08-08 | Protein domains and their ligands |
PCT/AU2002/001064 WO2003013523A1 (en) | 2001-08-08 | 2002-08-08 | Sh3 protein domains and their ligands |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPR6881A AUPR688101A0 (en) | 2001-08-08 | 2001-08-08 | Protein domains and their ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
AUPR688101A0 true AUPR688101A0 (en) | 2001-08-30 |
Family
ID=3830837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AUPR6881A Abandoned AUPR688101A0 (en) | 2001-08-08 | 2001-08-08 | Protein domains and their ligands |
Country Status (2)
Country | Link |
---|---|
AU (1) | AUPR688101A0 (en) |
WO (1) | WO2003013523A1 (en) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004064730A2 (en) | 2003-01-14 | 2004-08-05 | Cytokinetics, Inc. | Compounds, compositions and methods |
WO2005087775A1 (en) * | 2004-03-15 | 2005-09-22 | Ono Pharmaceutical Co., Ltd. | Tricyclic heterocyclic compound and medicinal composition containing the compound as active ingredient |
RU2410384C2 (en) | 2004-06-17 | 2011-01-27 | Цитокинетикс, Инк. | Compounds, compositions and methods of their application |
EP1781637A1 (en) * | 2004-06-29 | 2007-05-09 | Rigel Pharmaceuticals, Inc. | 2-substituted quinoline compounds and their uses as inhibitors of the ige receptor signaling cascade |
US7176222B2 (en) | 2004-07-27 | 2007-02-13 | Cytokinetics, Inc. | Syntheses of ureas |
US7538223B2 (en) | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
US8686002B2 (en) | 2005-08-21 | 2014-04-01 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as binding partners for 5-HT5 receptors |
US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
EP1959960B1 (en) | 2005-12-15 | 2013-04-10 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
WO2007078815A2 (en) | 2005-12-16 | 2007-07-12 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
WO2007078839A2 (en) | 2005-12-19 | 2007-07-12 | Cytokinetics, Inc. | Compounds, compositions and methods |
US9689879B2 (en) | 2006-08-21 | 2017-06-27 | Eidgenoessische Technische Hochschule Zurich | Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase |
US9513296B2 (en) | 2006-08-21 | 2016-12-06 | Eidgenoessische Technische Hochschule Zurich | Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase |
EP1892248A1 (en) * | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
EP2102165A2 (en) * | 2006-11-24 | 2009-09-23 | AC Immune S.A. | N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's |
PE20090717A1 (en) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS |
ES2394126T3 (en) * | 2007-07-26 | 2013-01-22 | Novartis Ag | Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions |
SI2195312T1 (en) | 2007-10-09 | 2013-01-31 | Merck Patent Gmbh | Pyridine derivatives useful as glucokinase activators |
EP2062578A1 (en) | 2007-11-12 | 2009-05-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Novel use of chemical compounds for the treatment of AIDS |
EP2440204B1 (en) | 2009-06-12 | 2013-12-18 | Bristol-Myers Squibb Company | Nicotinamide compounds useful as kinase modulators |
EP2311823A1 (en) | 2009-10-15 | 2011-04-20 | AC Immune S.A. | 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases |
JP6096807B2 (en) | 2012-01-13 | 2017-03-15 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Triazolyl-substituted pyridyl compounds useful as kinase inhibitors |
JP6096219B2 (en) | 2012-01-13 | 2017-03-15 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Triazolyl or triasiazolyl substituted pyridyl compounds useful as kinase inhibitors |
US9242975B2 (en) | 2012-01-13 | 2016-01-26 | Bristol-Myers Squibb Company | Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors |
US9546153B2 (en) | 2012-11-08 | 2017-01-17 | Bristol-Myers Squibb Company | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators |
US9657009B2 (en) | 2012-11-08 | 2017-05-23 | Bristol-Myers Squibb Company | Heteroaryl substituted pyridyl compounds useful as kinase modulators |
CA2891412A1 (en) | 2012-11-20 | 2014-05-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase |
EP2970199A1 (en) | 2013-03-11 | 2016-01-20 | Bristol-Myers Squibb Company | Isoquinolines as potassium ion channel inhibitors |
UY35935A (en) | 2014-01-03 | 2015-06-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | NICOTINAMIDE COMPOUNDS REPLACED WITH HETEROARILO AS QUINASE INHIBITORS AND MODULATORS OF IRAK-4 |
EP3265445B1 (en) * | 2015-03-06 | 2021-05-05 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
UY36748A (en) | 2015-06-24 | 2016-12-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | AMINOPIRIDINE COMPOUNDS REPLACED WITH HETEROARILO AS QUINASE INHIBITORS AND IRAK-4 MODULATORS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
TW201713663A (en) | 2015-06-24 | 2017-04-16 | 必治妥美雅史谷比公司 | Heteroaryl substituted aminopyridine compounds |
US10618903B2 (en) | 2015-06-24 | 2020-04-14 | Bristol-Myers Squibb Company | Heteroaryl substituted aminopyridine compounds |
JP6946412B2 (en) | 2016-07-18 | 2021-10-06 | ヤンセン ファーマシューティカ エヌ.ベー. | Tau PET Imaging Ligand |
EP3621960B1 (en) | 2017-05-11 | 2021-08-04 | Bristol-Myers Squibb Company | Thienopyridines and benzothiophenes useful as irak4 inhibitors |
CN113121658B (en) * | 2020-01-15 | 2022-10-21 | 中国农业大学 | Gene of protein containing SH3 structural domain in rhizobium and related biological material and application thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2312860C2 (en) * | 1999-04-15 | 2007-12-20 | Бристол-Маерс Сквибб Компани | Cyclic inhibitors of protein-tyrosine kinase |
-
2001
- 2001-08-08 AU AUPR6881A patent/AUPR688101A0/en not_active Abandoned
-
2002
- 2002-08-08 WO PCT/AU2002/001064 patent/WO2003013523A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2003013523A1 (en) | 2003-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AUPR688101A0 (en) | Protein domains and their ligands | |
AU2002310497A1 (en) | Protein aggregation assays and uses thereof | |
AU6058500A (en) | Fusion protein and uses thereof | |
AU2001251358A1 (en) | Prion-binding ligands and methods of using same | |
AU5340399A (en) | Proteases and associated proteins | |
AU2002305903A1 (en) | Carbohydrate-associated proteins | |
AU2001274566A1 (en) | Novel protein and dna thereof | |
AU2002357934A1 (en) | Humanized lactoferrin and uses thereof | |
AU2136401A (en) | P450rai-2 and related proteins | |
AU2002306077A1 (en) | Regulatory protein involved in pectin modification | |
AU2001280993A1 (en) | Tissue-associated proteins and their uses | |
AU2001244863A1 (en) | Apoptin-associating protein | |
AU2002254314A1 (en) | Trans inteins for protein domain shuffling and biopolymerization | |
AU3411999A (en) | Novel rnase-like protein and its use | |
AU2002319011A1 (en) | Sh3 protein domains and their ligands | |
AU2002240921A1 (en) | Medane genes and proteins | |
AU2002316348A1 (en) | Chimeric capsid proteins and uses thereof | |
AU2001250047A1 (en) | Effector-specific protein assembly and uses thereof | |
AU2001234150A1 (en) | Novel protein and gene encoding the same | |
GB0102447D0 (en) | Protein variants and uses thereof | |
AU2002357609A1 (en) | Novel proteins and dnas thereof | |
AU2001278777A1 (en) | Irap-binding protein | |
AU2002357850A1 (en) | Neurotransmission-associated proteins | |
AU2002230137A1 (en) | Novel protein and use thereof | |
AU2002219410A1 (en) | Ligands and their use |